Ac t i o n | 18 Aug 2026 08:46:54 ET │ 12 pages Amylyx Pharmaceuticals, Inc. (AMLX.O) Avexitide's phase 3 comes in with LUCIDITY; Raising TP to $32 CITI'S TAKE LUCIDITY delivered a strong phase 3 topline (preview here), with avexitide (GLP-1 antagonist) for post-bariatric hypoglycemia (PBH) reducing composite Level 2/3 hypoglycemic events by 55% vs. placebo (p=0.000003) and meeting all secondary endpoints. The magnitude replicated PREVENT's placebo-adjusted effect, exceeded the 35% treatment effect used to ...

Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia (PBH) Topline Data Conference Call August 18, 2026 Lindsey Allen Vice President, Investor Relations & Communications at Amylyx DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materi ...